急性髓性白血病中的NAP1L5:预后生物标志物和潜在的治疗标
Meng Wang1,2, Zhibin Xie2, Yuanyuan Tan2
1Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Anhui, Hefei, China.
Frontiers in oncology
|August 11, 2025
概括
核细胞组合蛋白1-like 5 (NAP1L5) 在急性髓性白血病 (AML) 中表达高,与预后不佳相关,并促进癌症生长. 针对NAP1L5可能为AML患者提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 核细胞组装蛋白1-like 5 (NAP1L5) 是基因转录和核细胞组装的调节者.
- NAP1L5与各种癌症的进展和不良预后有关.
- 在急性髓性白血病 (AML) 中NAP1L5的作用在很大程度上未被探索.
研究的目的:
- 研究NAP1L5在AML中的作用和分子机制.
- 确定NAP1L5作为潜在的预后生物标志物和AML的治疗点.
主要方法:
- 分析AML患者和健康对照组的基因表达特征.
- 差异表达分析,基因组丰富分析 (GSEA) 和基因本体学 (GO) 分析.
- 建立一个交互网络,预测模型,以及对免疫透和药物敏感性的评估.
- 在体外功能测试以探索生物功能.
主要成果:
- 在AML中增加NAP1L5表达与整体存活率降低有关.
- NAP1L5在亡和DNA复制途径中富含;共同表达的基因与自和应激反应有关.
- 高的NAP1L5与增加的休息CD4+记忆T细胞透和对齐博坦抗性的相关性.
- NAP1L5的过度表达促进AML细胞的增殖,迁移和殖民地形成,同时抑制细胞灭绝.
结论:
- NAP1L5是AML的一个有前途的预后生物标志物.
- NAP1L5代表了AML的潜在治疗标.
- 针对NAP1L5可能会改善患者的治疗结果,并使精确的治疗策略成为可能.
相关概念视频
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
02:39lncRNA - Long Non-coding RNAs
8.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K